Literature DB >> 20415602

RNA interference therapy for glioblastoma.

Dongsheng Guo1, Baofeng Wang, Fuxin Han, Ting Lei.   

Abstract

IMPORTANCE OF THE FIELD: Despite numerous advances made during the last decade in brain tumor therapy, the prognosis of glioblastoma has not improved and these tumors inevitably recur with no effective treatment. Thus, any new therapeutic strategy to target this most malignant tumor will be of significant benefit. RNAi is a powerful gene silencing method that might be used in combination with other agents to improve the efficacy of glioblastoma treatment. AREAS COVERED IN THIS REVIEW: Recent progress and challenges of pre-clinical and clinical research of RNAi therapy for glioblastoma. The review covers literature from 2003 to 2009. WHAT THE READER WILL GAIN: The principle of RNA interference therapy, three categories of RNAi triggers, different RNAi delivery system and pre-clinical and clinical studies that are currently underway to evaluate the validity of RNAi as a potential therapeutic strategy against glioblastoma are discussed. TAKE HOME MESSAGE: RNA inference therapy combined with other therapeutics may offer therapeutic potential for glioblastoma multiforme. Further studies are required to develop more efficient and specific delivery systems, select suitable gene targets, optimize treatment dose and administration schedule, evaluate the efficacy of combination treatment strategies, establish a validated clinical response measure system etc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20415602     DOI: 10.1517/14712598.2010.481667

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  10 in total

Review 1.  Current progress for the use of miRNAs in glioblastoma treatment.

Authors:  Amanda Tivnan; Kerrie Leanne McDonald
Journal:  Mol Neurobiol       Date:  2013-04-28       Impact factor: 5.590

2.  Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling.

Authors:  Linda C Hsi; Suman Kundu; Juan Palomo; Bo Xu; Ryan Ficco; Michael A Vogelbaum; Martha K Cathcart
Journal:  Mol Cancer Ther       Date:  2011-05-19       Impact factor: 6.261

Review 3.  Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies.

Authors:  Johan Karlsson; Kathryn M Luly; Stephany Y Tzeng; Jordan J Green
Journal:  Adv Drug Deliv Rev       Date:  2021-10-27       Impact factor: 17.873

Review 4.  Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Authors:  B Kalman; E Szep; F Garzuly; D E Post
Journal:  Neuromolecular Med       Date:  2013-04-11       Impact factor: 3.843

Review 5.  The protean world of non-coding RNAs in glioblastoma.

Authors:  Ramasamy Paulmurugan; Meenakshi Malhotra; Tarik F Massoud
Journal:  J Mol Med (Berl)       Date:  2019-05-25       Impact factor: 4.599

6.  Silencing of ferrochelatase enhances 5-aminolevulinic acid-based fluorescence and photodynamic therapy efficacy.

Authors:  L Teng; M Nakada; S-G Zhao; Y Endo; N Furuyama; E Nambu; I V Pyko; Y Hayashi; J-I Hamada
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

7.  Nucleic acids in human glioma treatment: innovative approaches and recent results.

Authors:  S Catuogno; C L Esposito; C Quintavalle; G Condorelli; V de Franciscis; L Cerchia
Journal:  J Signal Transduct       Date:  2012-05-21

Review 8.  Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma.

Authors:  Emily Padfield; Hayley P Ellis; Kathreena M Kurian
Journal:  Front Oncol       Date:  2015-01-29       Impact factor: 6.244

Review 9.  Glioblastoma multiforme - an overview.

Authors:  Kaja Urbańska; Justyna Sokołowska; Maciej Szmidt; Paweł Sysa
Journal:  Contemp Oncol (Pozn)       Date:  2014-08-04

10.  A peptide-mediated targeting gene delivery system for malignant glioma cells.

Authors:  Chuanwei Wang; Liping Ning; Hongwei Wang; Zaijun Lu; Xingang Li; Xiaoyong Fan; Xuping Wang; Yuguang Liu
Journal:  Int J Nanomedicine       Date:  2013-09-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.